Ceftolozane Sulfate; Tazobactam Sodium Patent Expiration
Ceftolozane Sulfate; Tazobactam Sodium is Used for treating complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, and ventilator-associated bacterial pneumonia. It was first introduced by Cubist Pharmaceuticals Llc
Ceftolozane Sulfate; Tazobactam Sodium Patents
Given below is the list of patents protecting Ceftolozane Sulfate; Tazobactam Sodium, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Zerbaxa | US10125149 | Synthesis of cephalosporin compounds | Aug 14, 2035 | Cubist Pharms Llc |
| Zerbaxa | US10376496 | Treating infections with ceftolozane/tazobactam in subjects having impaired renal function | Sep 09, 2034 | Cubist Pharms Llc |
| Zerbaxa | US10933053 | Treating infections with ceftolozane/tazobactam in subjects having impaired renal function | Sep 09, 2034 | Cubist Pharms Llc |
| Zerbaxa | US8906898 | Solid forms of ceftolozane | May 28, 2034 | Cubist Pharms Llc |
| Zerbaxa | US10420841 | Ceftolozane antibiotic compositions | Mar 14, 2034 | Cubist Pharms Llc |
| Zerbaxa | US11278622 | Ceftolozane antibiotic compositions | Mar 14, 2034 | Cubist Pharms Llc |
| Zerbaxa | US8968753 | Ceftolozane-tazobactam pharmaceutical compositions | Mar 14, 2034 | Cubist Pharms Llc |
| Zerbaxa | US9320740 | Ceftolozane-tazobactam pharmaceutical compositions | Mar 14, 2034 | Cubist Pharms Llc |
| Zerbaxa | US9872906 | Ceftolozane antibiotic compositions | Mar 14, 2034 | Cubist Pharms Llc |
| Zerbaxa | US8476425 | Tazobactam arginine compositions | Sep 27, 2032 | Cubist Pharms Llc |
| Zerbaxa | US8685957 | Tazobactam arginine compositions | Sep 27, 2032 | Cubist Pharms Llc |
| Zerbaxa | US10028963 | Methods for treating intrapulmonary infections | Sep 07, 2032 | Cubist Pharms Llc |
| Zerbaxa | US9724353 | Methods for treating intrapulmonary infections | Sep 07, 2032 | Cubist Pharms Llc |
| Zerbaxa | US7129232 | Cephem compounds | May 15, 2028 | Cubist Pharms Llc |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Ceftolozane Sulfate; Tazobactam Sodium's patents.
Latest Legal Activities on Ceftolozane Sulfate; Tazobactam Sodium's Patents
Given below is the list recent legal activities going on the following patents of Ceftolozane Sulfate; Tazobactam Sodium.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 08 Feb, 2023 | US10420841 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 11 Jan, 2023 | US10376496 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 11 May, 2022 | US8906898 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 12 Apr, 2022 | US10125149 |
| Recordation of Patent Grant Mailed Critical | 22 Mar, 2022 | US11278622 |
| Patent Issue Date Used in PTA Calculation Critical | 22 Mar, 2022 | US11278622 |
| Email Notification Critical | 03 Mar, 2022 | US11278622 |
| Issue Notification Mailed Critical | 02 Mar, 2022 | US11278622 |
| Application Is Considered Ready for Issue Critical | 10 Feb, 2022 | US11278622 |
| Dispatch to FDC | 10 Feb, 2022 | US11278622 |
Ceftolozane Sulfate; Tazobactam Sodium's Family Patents
